Transdermal buprenorphine in the treatment of chronic pain

References

• Staats PS, Johnson RE. New perspectives on the pharmacology of opioids and their use in chronic pain. Prog. Anesthesiol. 16, 235–249 (2002).
   Google Scholar
• Grossman SA, Benedetti C, Brock C et al. NCCN Practice Guidelines for Cancer Pain. NCCN Proceedings14, 135–150 (2000).
   Google Scholar
• Ferrell B, Casarett D, Epplin J et al. The management of persistent pain in older persons. J. Am. Geriatr. Soc. 50(Suppl. 6), S205–S224 (2002).
   Google Scholar
• Welsh J, Copp K, Dunne J et al. Control of pain in patients with cancer. A national clinical guideline. Edinburgh (Scotland). Scottish Intercollegiate Guidelines Network, 2000, 1–6 (1996).
   Google Scholar
• Masson AHB. Sublingual buprenorphine versus oral dihydrocodeine in post-operative pain. J. Int. Med. Res.9, 506–510 (1981).
   PubMed Web of Science ®Google Scholar
• Hanks GW. The clinical usefulness of agonist-antagonist opioid analgesics in chronic pain. Drug Alcohol Depend. 20, 339–46 (1987).
   PubMed Web of Science ®Google Scholar
• Heel RC, Brogden RN, Speight TM, Avery GS. Buprenorphine: a review of its pharmacological properties and therapeutic efficacy. Drugs17, 81–119 (1979).
   PubMed Web of Science ®Google Scholar
• Budd K. Buprenorphine and the transdermal system: the ideal match in pain management. Int. J. Clin. Pract.133(Suppl.), 9–14 (2003).
   Google Scholar
• Allan L, Hays H, Jensen NH et al. Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. Br. Med. J. 322, 1154–1158 (2001).
   PubMed Web of Science ®Google Scholar
• Payne R, Mathias SD, Pasta DJ et al. Quality of life and cancer pain: satisfaction and side effects with transdermal fentanyl versus oral morphine. J. Clin. Oncol. 16, 1588–1593 (1998).
   PubMed Web of Science ®Google Scholar
• Grünenthal GmbH. Transtec Scientific Monograph. (2002).
   Google Scholar
• Martin WR, Eades CG, Thompson JA et al. The effects of morphine- and nalorphine-like drugs in the nondependent and morphine-dependent chronic spinal dog. J. Pharmacol. Exp. Ther. 197, 517–532 (1976).
   PubMed Web of Science ®Google Scholar
• Lewis JW. Buprenorphine. Drug Alcohol. Depend. 14, 363–372 (1985).
   PubMed Web of Science ®Google Scholar
• Cowan A, Doxey JC, Harry EJR. The animal pharmacology of buprenorphine, an oripavine analgesic agent. Br. J. Pharmacol. 60, 547–554 (1977).
   PubMed Web of Science ®Google Scholar
• Leander JD. Buprenorphine is a potent κ-opioid receptor antagonist in pigeons and mice. Eur. J. Pharmacol. 151, 457–461 (1988).
   PubMed Web of Science ®Google Scholar
• Cowan A, Lewis JW, Macfarlane IR. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. Br. J. Pharmacol. 60, 537–545 (1977).
   PubMed Web of Science ®Google Scholar
• Evans HC, Easthope SE. Transdermal buprenorphine. Drugs 63, 1999–2010 (2003).
   PubMed Web of Science ®Google Scholar
• Dunn JE, Herz A. In vivo receptor binding of the opiate partial agonist, buprenorphine, correlated with its agonistic and antagonistic actions. Br. J. Pharmacol. 74, 627–633 (1981).
   PubMed Web of Science ®Google Scholar
• Tyers MB. A classification of opiate receptors that mediate antinociception in animals. Br. J. Pharmacol.69, 503–512 (1980).
   PubMed Web of Science ®Google Scholar
• Budd K. High-dose buprenorphine for postoperative analgesia. Anaesthesia36, 900–903 (1981).
   PubMed Web of Science ®Google Scholar
• Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of buprenorphine: ceiling effects at high doses. Clin. Pharmacol. Ther. 55, 569–580 (1994).
   PubMed Web of Science ®Google Scholar
• Dahan A, Bijl H, Romberg R et al. Full reversal of buprenorphine induced respiratory depression by naloxone. Eur. J. Anaesthesiology (2005) (In Press).
   Google Scholar
• Tegeder I, Lotsch J, Geisslinger G. Pharmacokinetics of opioids in liver disease. Clin. Pharmacokinet. 37, 17–40 (1999).
   PubMed Web of Science ®Google Scholar
• Budd K. Buprenorphine: a review. Evidence Based Med. Prac. 1–24 (2002).
   Google Scholar
• Böhme K. Buprenorphine in a transdermal therapeutic system – a new option. Clin. Rheumatol. 21(Suppl. 1), S13–S16 (2002).
   PubMedGoogle Scholar
• Data on file. Grünenthal. (2003).
   Google Scholar
• Sittl R. Buprenorphine transdermal patch: clinical expert report. Grünenthal, GmbH, Germany (2000).
   Google Scholar
• Rance MJ, Shillingford JS. The role of the gut in the metabolism of strong analgesics. Biochem. Pharmacol.25, 735–741 (1976).
   PubMed Web of Science ®Google Scholar
• Rance MJ, Shillingford JS. The metabolism of phenolic opiates by rat intestine. Xenobiotica 7(9), 529–536 (1997).
   Google Scholar
• Iribarne C, Picart D, Dreano Y, Bail JP, Berthou F. Involvement of cytochrome P450 3A4 in N-dealkylation of buprenorphine in human liver microsomes. Life Sci. 60, 1953–1964 (1977).
   Google Scholar
• Ohtani M, Kotaki H, Nishitateno K. Kinetics of resoiratory depression in rats induced by buprenorphine and its metabolite, norbuprenrophine. J. Pharmacol. Exp. Ther. 281(1), 428–433 (1984).
   Google Scholar
• Filitz J, Sittl R, Griessinger N, Likar R, Koppert W. Pharmacokinetics of transdermal buprenorphine (Transtec®) in patients with renal insufficiency. Poster presented at EAPC in Aachen. J. Pain Symptom Manage. (2005) (In Press).
   Google Scholar
• McQuay HJ, Moore RA, Bullingham RES. Buprenorphine kinetics. In: Advancesin Pain Research and Therapy. Foley KM, Inturrisi CE (Eds). Raven Press, NY, USA, 271–278 (1986).
   Google Scholar
• Moore RA, Sear JW, Baldwin D et al. Morphine kinetics during and after renal transplantation in man. Clin. Pharmacol. Ther. 35, 641–645 (1997).
   Google Scholar
• Böhme K. Buprenorphine transdermal system (TDS) (delivery rates 35/52.5/70 µg/h) in comparison to sublingual buprenorphine in chronic pain patients. 1st Congress of the Research Network of the European Association for Palliative Care, December 7–9, Berlin, Germany (2000).
   Google Scholar
• Böhme K, Likar R. Efficacy and tolerability of a new opioid analgesic formulation, buprenorphine transdermal therapeutic system (TDS), in the treatment of patients with chronic pain. A randomized, double-blind, placebo-controlled study. Pain Clinic 15, 193–202 (2003).
   Web of Science ®Google Scholar
• Sittl R, Griessinger N, Likar R. Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin. Ther. 25, 150–68 (2003).
   PubMed Web of Science ®Google Scholar
• Sorge J, Sittl R. Transdermal buprenorphine in the treatment of chronic pain: results of a Phase III, multicenter, randomized, double-blind, placebo-controlled study. Clin. Ther. 26(11), 1808–1820 (2004).
   PubMed Web of Science ®Google Scholar
• Radbruch L. Buprenorphine TDS: use in daily practice, benefits for patients. Int. J. Clin. Pract. (Suppl. 13), 19–22 (2003).
   Google Scholar
• Kopp M. Buprenorphine transdermal system (TDS) in an open long-term study with chronic pain patients. 1st Congress of the Research Network of the European Association for Palliative Care, December 7–9, Berlin, Germany (2000).
   Google Scholar
• Vielvoye-Kerkmeer APE. Long-term treatment with buprenorphine TDS in patients with chronic pain. Eur. J. Palliat. Care 10(Suppl. 1), 17–19 (2003).
   Google Scholar
• Liedgens H, Ritzdorf I. Efficacy and safety of transdermal buprenorphine demonstrated in a large chronic pain population. Schmerz 17(Suppl. 1), S104–S105 (2003).
   Google Scholar
• Twycross RG. Opioid analgesics in cancer pain: current practice and controversies. Cancer Surveys 7, 29–53 (1988).
   PubMedGoogle Scholar
• Atkinson RE, Schofield P, Mellor P. The efficacy in sequential use of buprenorphine and morphine in advanced cancer pain. In: Opioids in the Treatment of Cancer Pain. Doyle D (Ed.). Royal Society of Medicine Services, International Congress and Symposium Series. 146, 81–87 (2004).
   Google Scholar
• Camba MA, The Opioid Study Group of the Spanish Pain Society. Transdermal buprenorphine for the management of nociceptive chronic pain. Rev. Soc. Esp. Dolor. (Suppl V), 22–30 (1990).
   Google Scholar
• Rodriguez-Lopez MJ, The Opioid Study Group of the Spanish Pain Society. Transdermal buprenorphine in the management of neuropathic pain. Rev. Soc. Esp. Dolor. (Suppl. V), 11–21 (2004).
   Google Scholar
• Muriel C, The Opioid Study Group of the Spanish Pain Society. Assessment of buprenorphine transdermal patch in patients with cancer pain. Rev. Soc. Esp. Dolor. (Suppl. V), 41–48 (2004).
   Google Scholar
• Barutell C de, The Opioid Study Group of the Spanish Pain Society. Buprenorphine and tramadol. Rev. Soc. Esp. Dolor. (Suppl. V), 31–40 (2004).
   Google Scholar
• Gonzalez-EscaladaJR, The Opioid Study Group of the Spanish Pain Society. Use of buprenorphine and oral morphine in patients with chronic pain. Rev Soc Esp Dolor (Suppl. V), 3–10 (2004).
   Google Scholar
• Gal TJ. Naloxone reversal of buprenorphine-induced respiratory depression. Clin. Pharmacol. Ther. 45, 66–71 (1989).
   PubMed Web of Science ®Google Scholar
• Knape JTA. Early respiratory depression resistant to naloxone following epidural buprenorphine. Anesthesiology 64, 382–384 (1986).
   PubMed Web of Science ®Google Scholar
• Haddox JD, Joranson D, Angarola RT et al. The use of opioids for the treatment of chronic pain: a consensus statement from American Academy of Pain Medicine and American Pain Society www.ampainsoc.org/cgi-bin/print/print.pl (Accessed April 2005)
   Google Scholar
• World Health Organization. World Health Organization’s pain relief ladder. www.who.int/cancer/palliative/ painladder/en/ (Accessed April 2005)
   Google Scholar